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Objectives: To evaluate the survival and prognostic implications of cardiovascular, inﬂammatory and
prothrombotic risk factors in young patients with premature coronary heart disease (CHD).
Methods: Follow-up data were obtained from 353 young patients with a ﬁrst cardiac event (men 45
years and women 55 years). Baseline characteristics on traditional risk factors were collected at the
time of the ﬁrst event, and plasma levels of C-reactive protein (CRP), von Willebrand Factor (VWF), and
ﬁbrinogen were measured one to three months after the ﬁrst event to exclude an acute phase response.
We performed age and sex adjusted Cox regression analyses to assess the relationship between these
factors and recurrent events with three different endpoints: all cause mortality, recurrent cardiac event
(myocardial infarction or revascularisation procedure), and any recurrent event (cardiac event, cere-
brovascular event or all cause mortality).
Results: During a total follow-up time of 1483 person years (mean 4.2 years), 11 patients died (3%), 42
patients had a recurrent cardiac event (12%), and 53 patients had any recurrent event (15%). CRP was
associated with an increased risk of any recurrent event (HR 1.28[95% CI ¼ 1.02e1.59] per unit increase in
lnCRP). Also, both CRP (5.00[1.04e24.04]) and ﬁbrinogen (5.04[1.05e24.23]) were associated with all
cause mortality when levels were above the 50th percentile.
Conclusions: Fifteen percent of young patients with a ﬁrst cardiac event have a recurrent event or die
within a median follow-up of 4.2 years. In these young patients we have shown that, independently of
cardiovascular risk factors, high CRP levels contribute to the risk of recurrent events, including all cause
mortality, and high ﬁbrinogen levels are associated with all cause mortality.
 2012 Elsevier Ireland Ltd. Open access under the Elsevier OA license.1. Introduction
Despite many improvements in medical treatment, coronary
heart disease (CHD) is still a major health concern in today’s clinical
practice. Only a very small percentage (<10%) of all patients with
myocardial infarction is below the age of 45 years [1,2]. However,
the number of young individuals with coronary atherosclerosis is
probably much larger than can be currently estimated. Autopsies
have shown that about 50% of young individuals have coronary
atherosclerosis [3]. Few studies have accomplished to include
sufﬁciently large groups of young CHD patients to investigate their
risk proﬁles and prognosis. However, there is a growing need to
identify those at risk for recurrent events, since especially youngL-435), Erasmus University
he Netherlands. Tel.: þ31 10
eebeek).
der the Elsevier OA license.CHD patients comprise an interesting group for preventive
cardiology.
Generally, young subjects with CHD have multiple traditional
risk factors and have a different risk proﬁle than older patients
[4,5]. Also, the occurrence of recurrent symptoms and events is
surprisingly common. Reported long-term event rates including
mortality are as high as 50% [6,7]. The main predictors of long-term
recurrent events and mortality in young subjects that have been
established over the years are diabetes, a low ejection fraction,
atrial ﬁbrillation, use of antiarrhythmic drugs, continued smoking,
and plasma plasminogen activator inhibitor (PAI-1) concentration
[5e7]. Moreover, there is a growing believe that prognostic risk
factors differ between men and women.
In the last few decades novel risk factors for CHD have been
identiﬁed in previously healthy subjects. Examples of these are
inﬂammatory markers, such as C-reactive protein (CRP), and pro-
thrombotic markers, including von Willebrand Factor (VWF) and
ﬁbrinogen [8e11]. However, information on their predictive value
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very scarce.
Considering the necessity to recognize young CHD patients at
risk for a recurrent event and to improve prevention strategies in
this special group of patients, we aimed to evaluate the prognostic
implications of traditional risk factor, CRP, VWF, and ﬁbrinogen in
a unique and relatively large cohort of young patients with a ﬁrst
acute coronary syndrome.
2. Methods
2.1. Patients
This follow-up study is a sub-study of the ‘Genetic risk factors
for Arterial Thrombosis at young age: the role of TAFI and other
Coagulation factors’ (ATTAC) study. The ATTAC study is a single-
center, case-control study, described in more detail previously
[12]. For this sub-study we obtained follow-up data from all cardiac
patients (N ¼ 385), who were consecutively recruited one to three
months after their ﬁrst event (acute myocardial infarction or
unstable angina pectoris) at the department of Cardiology at the
Erasmus Medical Center Rotterdam between 2001 and 2010.
Patients were eligible for inclusionwhen theywere 18e45 years for
males and 18e55 years for females at the time of diagnosis. The
follow-up study was approved by the medical research board at
Erasmus University Medical Center and written informed consent
was obtained from all participants at inclusion.
After all cardiac patients were asked to participate in the follow-
up study, data on their current health status were obtained via
a telephone interview and veriﬁed in medical records. We used
three different endpoints: all cause mortality, recurrent cardiac
event, which was deﬁned as a myocardial infarction, percutaneous
coronary intervention or coronary artery bypass graft surgery, and
any recurrent event, including a cardiac event (myocardial infarc-
tion or revascularisation procedure), cerebrovascular event (CVA or
TIA) or all cause mortality.
Of all cardiac patients, 22 patients were lost to follow-up, mainly
because of emigration or because their contact information had
changed and could not be traced down. Ten patients gave no
permission for the follow-up study. We could include 353 cardiac
patients in our analyses. Between the ﬁrst event and the start of the
follow-up study eleven patients died. Since we could not obtain
informed consent of these patients to investigate their cause of
death, we classiﬁed these patients as deaths of any cause.
2.2. Blood sampling
Blood was drawn one to three months after the ﬁrst ischemic
event by venipuncture in the antecubital vein using the Vacutainer
system (BectoneDickinson, Plymouth, UK). Blood for coagulation
measurements was collected in 3.2% trisodium citrate (9:1 vol/vol).
Citrated blood was centrifuged within 1 h at 2000  g for 10 min at
4 C. Plasma was additionally centrifuged at 14,000  g for 10 min
at 4 C and stored in aliquots at 80 C.
2.3. Laboratory measurements
CRP was determined in serum using Rate Near Infrared Particle
Immunoassay (Immage Immunochemistry System, Beckman
Coulter, USA). This system measures concentrations ranging from
0.2 to 1440 mg/L, with a within-run precision <5.0%, a total
precision <7.5%, and a reliability coefﬁcient of 0.995.
VWF antigen (VWF:Ag) was determined at baseline with an in-
house ELISA with polyclonal rabbit anti-human VWF antibodies
and horseradish peroxidase conjugated anti-human VWFantibodies (DakoCytomation, Glostrop, Denmark) for catching and
tagging, respectively. The intra-assay coefﬁcient of variation was
5.7%, and the interassay coefﬁcient of variation was 7.8%.
Plasma ﬁbrinogenwasmeasured as described by von Clauss [13]
on the Sysmex CA 1500 coagulation analyzer (Dade Behring,
Leusden, Netherlands). The within-day variation was 1.7% and the
between-day variation 6.3%.
Cholesterol and HDL were determined on Modular Analytics
(Roche Diagnostics, Mannheim, Germany). The total assay variation
was 3% and 2% for cholesterol and HDL, respectively.
2.4. Statistical analysis
Data on population characteristics are presented as means and
standard deviations for continuous variables and as counts and
percentages for categorical data. Since CRP and VWF:Ag levels were
skewed, these data were natural logarithmically transformed
(lnCRP and lnVWF:Ag, respectively) and presented as geometric
mean and standard deviation. We used Cox regression analyses
adjusted for age and sex to assess the relationship between the
selected markers and the risk of recurrent events. For the associa-
tion between traditional cardiovascular risk factors and the risk of
recurrent events a sex-speciﬁc analysis was performed additionally.
Since CRP, VWF, and ﬁbrinogen are associated with cardiovascular
risk factors, all associations were adjusted additionally for cardio-
vascular risk factors present at inclusion (family history of cardio-
vascular disease, hypertension, diabetes, cholesterol, high-density
lipoprotein, hypercholesterolemia, BMI and smoking). The analyses
with all cause mortality as endpoint were not adjusted for sex or
diabetes, since only one of all deaths was female and none had
diabetes. Levels of CRP, VWF and ﬁbrinogen were divided into two
groups: below and above the 50th percentile. Cut-off level for CRP
was 0.87 mg/L, for VWF 1.23 IU/mL, and 3.4 g/L for ﬁbrinogen.
Cumulative survival curves and cumulative event-free survival
curves were constructed using the KaplaneMeier (KM) method. In
order to compare the KM-curves we used a Log-rank test.
Statistical analyses were performed with SPSS for Windows,
version 17.0 (SPSS Inc, Chicago, USA). A two-sided value of p < 0.05
was considered statistically signiﬁcant.
3. Results
Our study population consists of 353 patients with a total
follow-up of 1483 person years (mean  SD, 4.2  2.6 years).
Baseline characteristics are shown in Table 1, as well as the refer-
ence values and the baseline characteristics of 487 control subjects
that were included in the ATTAC study. Of all cardiac patients, 299
had a myocardial infarction as ﬁrst event and 54 had unstable
angina pectoris as ﬁrst event. Most patients received a drug-eluting
stent (91%) and had single vessel disease (76%). Left ventricular
ejection fraction was available in 109 subjects: good (>55%) in 73
subjects, moderate (40e55%) in 32 subjects, and poor (<40%) in 4
subjects.
During follow-up, 11 patients died of any cause (3%), 42 patients
had a recurrent cardiac event (12%), and two patients had a cere-
brovascular event (<1%). The mean age of the total follow-up
cohort was 43.8 years and 156 (44%) patients were female. Of all
patients, 98% was on anti-platelet therapy (aspirin and/or clopi-
dogrel), 95% used statins, and 94% used any blood pressure
lowering drugs, including bèta-blockers, ACE-inhibitors, calcium
antagonists, diuretics or angiotensin-II receptor antagonists. In the
total group, both age and sex did not differ between patients who
had a recurrent event and patients without reinfarction.
Classical cardiovascular risk factors were not associated with
recurrent cardiac events (Table 2). However, in a sex-speciﬁc
Table 2
Association between traditional cardiovascular risk factors and the risk of recurrent
events.
All cause
mortality
HR (95% CI)
Recurrent
cardiac
event HR
(95% CI)
Any recurrent
event HR
(95% CI)
Age 0.98 (0.89e1.08) 0.98 (0.93e1.03) 0.99 (0.94e1.03)
Female sex e 1.26 (0.68e2.33) 0.98 (0.57e1.67)
Family history
of cardiovascular
disease
0.69 (0.19e2.43) 0.96 (0.52e1.78) 0.91 (0.53e1.56)
Hypertension 0.26 (0.03e2.04) 0.59 (0.26e1.34) 0.56 (0.27e1.14)
Diabetes e 1.88 (0.84e4.25) 1.39 (0.63e3.07)
Smoking, current 0.40 (0.09e1.67) 2.07 (0.96e4.43) 1.42 (0.76e2.66)
Smoking, former 1.34 (0.32e5.60) 1.96 (0.73e5.28) 1.66 (0.74e3.69)
Total cholesterol 1.47 (0.77e2.81) 1.11 (0.79e1.56) 1.17 (0.88e1.57)
HDL 1.31 (0.29e6.01) 1.20 (0.55e2.59) 1.29 (0.66e2.51)
Hypercholesterolemia 1.72 (0.44e6.68) 1.01 (0.54e1.91) 1.10 (0.63e1.92)
BMI 0.94 (0.82e1.08) 0.99 (0.93e1.06) 0.98 (0.93e1.04)
Cox regression analysis to assess the relationship between traditional cardiovas-
cular risk factors and the risk of recurrent events. Recurrent cardiac event was
deﬁned as a myocardial infarction or revascularisation procedure. Any recurrent
event was deﬁned as a cardiac event, a cerebrovascular event or all cause mortality.
Data are presented as hazard ratios with 95% conﬁdence intervals. Analyses with the
endpoint all cause mortality were not performed for female sex (number of
event ¼ 1) and diabetes (number of event ¼ 0).
Table 3
Adjusted association between inﬂammatory and prothrombotic markers and the
risk of recurrent events.
Variable Model 1 HR (95% CI) Model 2 HR (95% CI)
All cause mortality
lnCRP 1.56 (0.92e2.63) 1.80 (0.95e3.39)
lnVWF:Ag 0.90 (0.22e3.64) 1.33 (0.21e8.23)
Fibrinogen 1.85 (0.91e3.80) 1.79 (0.80e3.97)
Recurrent cardiac event
lnCRP 1.23 (0.96e1.59) 1.21 (0.90e1.63)
lnVWF:Ag 1.12 (0.53e2.36) 1.10 (0.48e2.56)
Fibrinogen 0.87 (0.53e1.40) 0.88 (0.52e1.50)
Any recurrent event
lnCRP 1.28 (1.02e1.59) 1.35 (1.03e1.77)
lnVWF:Ag 1.06 (0.54e2.05) 1.20 (0.55e2.62)
Fibrinogen 1.05 (0.70e1.57) 1.15 (0.74e1.77)
Cox regression analysis to assess the relationship between selected biomarkers
(CRP, vonWillebrand Factor, and ﬁbrinogen) and the risk of a recurrent event. lnCRP
and lnVWF:Ag are the natural logarithmically transformed CRP and vWF:Ag levels.
Recurrent cardiac event was deﬁned as a myocardial infarction or revascularisation
procedure. Any recurrent event was deﬁned as a cardiac event, a cerebrovascular
event or all causemortality. Data are presented as hazard ratios with 95% conﬁdence
intervals per unit increase in lnCRP, lnVWF, and ﬁbrinogen, respectively. Model 1 is
adjusted for age and sex. Model 2 is additionally adjusted for family history of
cardiovascular disease, hypertension, diabetes, cholesterol, high-density lipopro-
tein, hypercholesterolemia, BMI and smoking. The analyses with all cause mortality
as endpoint were not adjusted for sex or diabetes.
Table 1
Baseline characteristics.
Cardiac
patients
N ¼ 353
Controls
ATTAC study
N ¼ 487
Reference
values
Age (years) 43.8  5.9 38.8  7.8
Female sex, N (%) 156 (44%) 293 (63%)
First event
Myocardial infarction 299 (85%)
NSTEMI 232 (89%)
STEMI 30 (11%)
Unstable angina pectoris 54 (15%)
Family history of
cardiovascular disease, N (%)
173 (49%) 112 (23%)
Hypertension, N (%) 88 (25%) 30 (7%)
Diabetes, N (%) 35 (10%) 8 (2%)
Smoking, current, N (%) 133 (38%) 123 (25%)
Smoking, former, N (%) 165 (47%) 129 (27%)
Total cholesterol (mmol/L) 4.2  0.9 5.0  0.9 2.9e6.5
HDL (mmol/L) 1.2  0.4 1.5  0.4 >1.55
Hypercholesterolemia, N (%) 172 (49%) 167 (42%)
BMI (kg/m2) 27  5 25  4
Bèta-blockers, N (%) 291 (82%) 14 (3%)
ACE-inhibitors, N (%) 210 (60%) 4 (1%)
Diuretics, N (%) 22 (6%) 8 (2%)
Calcium antagonists, N (%) 31 (9%) 2 (0.4%)
Angiotensin-II receptor
antagonists, N (%)
14 (4%) 7 (2%)
Statins, N (%) 336 (95%) 8 (2%)
Anti-platelet drugs, N (%) 347 (98%) 6 (1%)
CRP (mg/L) 0.78  2.1 0.65  1.9 0.2e7.3
VWF:Ag (IU/mL) 1.19  0.7 1.04  0.4 0.60e1.40
Fibrinogen (g/L) 3.45  0.7 ND 1.5e3.6
Summary statistics for continuous variables are presented as mean  standard
deviation. Categorical data are summarized as percentages.
ND ¼ not determined.
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[95% CI ¼ 1.02e6.94]) and a recurrent cardiac event (4.11 [95%
CI ¼ 1.50e11.27]) in men. In women, current smoking and former
smoking were signiﬁcantly associated with both recurrent cardiac
event and any recurrent event. Current smoking had an HR of 6.61
[95% CI ¼ 1.52e28.78] for any recurrent event and an HR of 12.3
[95% CI ¼ 1.63e93.45] for a recurrent cardiac event. Former
smoking had an HR of 5.96 [95% CI ¼ 1.16e30.71] for any recurrent
event and an HR of 9.82 [95% CI ¼ 1.10e87.88] for a recurrent
cardiac event.
CRP levels were higher in patients who died of any cause
(1.04 mg/L), in patients with a recurrent cardiac event (1.02 mg/L),
and in patients with any recurrent event (1.06 mg/L) than in
patients without reinfarction (0.73 mg/L). The age and sex adjusted
hazard ratios per unit increase in lnCRP levels were 1.56 [95%
CI¼ 0.92e2.63] for all cause mortality, 1.23 [95% CI¼ 0.96e1.59] for
a recurrent cardiac event, and 1.28 [95% CI ¼ 1.02e1.59] for any
recurrent event (Table 3). In a multivariate model including all
traditional risk factors the hazard ratios per unit increase in lnCRP
levels were 1.80 [95% CI ¼ 0.95e3.39] for all cause mortality, 1.21
[95% CI ¼ 0.90e1.63] for a recurrent cardiac event, and 1.35 [95%
CI ¼ 1.03e1.77] for any recurrent event. Patients with CRP levels
above the 50th percentile had a 5-fold increased risk of all cause
mortality (HR 5.00 [95% CI ¼ 1.04e24.04]). Moreover, it is clearly
shown that subjects with the highest CRP levels have a lower
cumulative survival (93%) than subjects with the lowest CRP levels
(99%, log-rank test p < 0.05) (Fig. 1A). Also, the cumulative event-
free survival was lower in subjects with the highest CRP levels
(78%) than in subjects with the lowest CRP levels (81%, log-rank test
p ¼ 0.13), though just below the statistical signiﬁcance level
(Fig. 1B).
The mean ﬁbrinogen levels were 3.8  0.7 g/L in patients who
died of any cause, 3.4  0.9 g/L in patients with a recurrent cardiacevent, 3.4  0.9 g/L in patients with any recurrent event, and
3.5 0.7 g/L in patients without reinfarction. High ﬁbrinogen levels
wereweakly correlated with an increased risk of all cause mortality
only (Table 3). Subjects with ﬁbrinogen levels above the 50th
percentile had a signiﬁcantly increased risk of all cause mortality
(HR 5.04 [95% CI ¼ 1.05e24.23]), also after adjustment for classical
cardiovascular risk factors (HR 10.41 [95% CI ¼ 1.18e91.80]). The
cumulative survival of patients with the highest ﬁbrinogen levels
was 94% compared to 98% in patients with the lowest ﬁbrinogen
levels (Log-rank test p ¼ 0.05) (Fig. 2A).
The mean VWF:Ag levels were 1.1  1.0 IU/mL in patients who
died of any cause, 1.2  0.5 IU/mL in patients with a recurrent
cardiac event, 1.2  0.6 IU/mL in patients with any recurrent event,
and 1.2  0.7 IU/mL in patients without reinfarction. VWF:Ag levels
were not associated with recurrent events (Table 3).
Fig. 1. Cumulative survival for CRP levels below and above the 50th percentile
KaplaneMeier curve for cumulative survival (A) and cumulative event-free survival (B)
For CRP levels above and below the 50th percentile. The cut-off value was 0.87 mg/L.
Fig. 2. Cumulative survival for ﬁbrinogen levels below and above the 50th percentile
KaplaneMeier curve for cumulative survival (A) and cumulative event-free survival (B)
For ﬁbrinogen levels above and below the 50th percentile. The cut-off value was
3.4 g/L.
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In this follow-up study of young patients with premature CHD
ﬁfteen percent had a recurrent cardiac event or died of any cause
within amedian follow-up period of 4.2 years. In addition, high CRP
levels contributed to the risk of recurrent events and all cause
mortality. High ﬁbrinogen levels were associated with all cause
mortality only.
The independent relationship between CRP levels and all cause
mortality or any recurrent event was yet unknown in young
patients with CHD. Since we measured CRP levels one to three
months after the ﬁrst event, our ﬁndings are less inﬂuenced by an
acute phase response that follows infarction. This is in contrast to
many other studies that measured CRP levels at the onset of a ﬁrst
myocardial infarction. Some studies showed that CRP levels during
acute myocardial infarction predict 30-day and long-termmortality
[14,15], whereas other studies did not show this relationship
[16e18]. CRP levels measured at the time of an acute myocardial
infarction may reﬂect the severity of disease at that time point and
may therefore not be useful for long-term cardiovascular assess-
ment. Harb et al. measured CRP levels two months after a myocar-
dial infarction. Although they showed that CRP levels tended to be
higher in patients with recurrent events, CRP was not an inde-
pendent marker for recurrent events in a multivariate model [19].
In addition, we found a signiﬁcant association between high
ﬁbrinogen levels and all cause mortality, even after adjustment forcardiovascular risk factors. Studies on the predictive value of
ﬁbrinogen for recurrent cardiovascular events are scarce. One study
reported an association between ﬁbrinogen levels and the risk of
coronary events in patients with stable coronary artery disease
[20]. Also, a study of Pineda et al. in young subjects with coronary
artery disease (median age 41 years) showed that ﬁbrinogen was
predictive for cardiovascular events, though only in the unadjusted
analysis [21].
No relation was found between VWF levels and the risk of
recurrent events. VWF:Ag levels have been associated with rein-
farction and/or mortality risk in patients with CHD by numerous
studies [22]. However, these patients were generally much older
than our current study population. Pineda et al. investigated the
prognostic implications of VWF:Ag levels in young patients with
a ﬁrst myocardial infarction [21]. In the current study therewas also
no association between VWF:Ag levels and cardiovascular events
observed.
Since the inﬂammatory markers CRP and ﬁbrinogen, but not
VWF, were associated with recurrent events or all cause mortality,
our results suggest that inﬂammation is an important determinant
of prognosis. Indeed, there is a strong cross-talk between inﬂam-
mation and thrombosis [23]. Inﬂammationhas been associatedwith
the occurrence of myocardial infarction [24,25]. The absence of an
association in young CHD patients between VWF:Ag levels and
recurrent events in our study and in previous studies is an
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risk factor for CHD in older subjects. Levels of VWF:Ag mirror the
extent of endothelial dysfunction and thereby the atherosclerosis
burden in the body. Since CRP and ﬁbrinogen, but not VWF, were
associated with recurrent events or all cause mortality, we hypoth-
esize that at young age inﬂammation, as reﬂected by the CRP and
ﬁbrinogen levels, is more important than the extent of atheroscle-
rosis for prognosis. However, considering the number of recurrent
events in our study our results should be interpreted with care.
Surprisingly, traditional cardiovascular risk factors were not
associatedwith recurrent events in the total group.However, since it
is suspected that there are strong gender differences in prognostic
markers we performed a sex-speciﬁc analysis. In this analysis dia-
betes was associated with recurrent events in men. In women both
former smoking and current smoking were associated with recur-
rent events. However, considering the small numbers in this sub-
analysis larger studies are required to investigate this inmore detail.
In our study, 98% of all cardiac patients were on anti-platelet
therapy, 95% used statins, and 94% used any blood pressure
lowering drug. It is interesting that despite optimal medical therapy
these young patients experience this many recurrent events (15%),
although the survival after a ﬁrst cardiac event is excellent (97%).
Recently, in a large group of young patients (50 years) undergoing
PCI it has been shown that the long-termoutcomehas not changed in
the last 30 years despite improved secondary prevention [26]. These
ﬁndings imply a negative trend in risk proﬁles of young individuals or
that current treatment strategies are possibly still not adequate.
Although our study comprises a considerable large group of
young subjects with premature CHD followed in time, our study
was still limited by the number of patients and the number of
recurrent events. Also, since we included patients after one to three
months, we possibly missed patients who had a recurrent event
before inclusion or patients who died shortly after the ﬁrst event.
Finally, CRP and ﬁbrinogen were signiﬁcantly associated with
respectively a recurrent event and all cause mortality, though their
effect sizes were modest. Nevertheless, the ﬁndings of the current
study clearly illustrate that the risk proﬁles in young CHD patients
are different than the risk proﬁles at older age and that the
prevention strategies should be adapted to this.
In conclusion, we show that although the survival after a ﬁrst
cardiac event in young patients is good, the recurrent event rate is
quite high despite optimal medical therapy. In addition, in these
young patients high CRP levels contribute to the risk of recurrent
events and high ﬁbrinogen levels are associated with all cause
mortality independently of cardiovascular risk factors.
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